These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26354972)

  • 1. Management of Brugada Syndrome: Thirty-Three-Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs.
    Belhassen B; Rahkovich M; Michowitz Y; Glick A; Viskin S
    Circ Arrhythm Electrophysiol; 2015 Dec; 8(6):1393-402. PubMed ID: 26354972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine.
    Bouzeman A; Traulle S; Messali A; Extramiana F; Denjoy I; Narayanan K; Marijon E; Hermida JS; Leenhardt A
    Europace; 2014 Apr; 16(4):572-7. PubMed ID: 24068450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome.
    Belhassen B; Glick A; Viskin S
    Pacing Clin Electrophysiol; 2009 Mar; 32(3):294-301. PubMed ID: 19272057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of quinidine in high-risk patients with Brugada syndrome.
    Belhassen B; Glick A; Viskin S
    Circulation; 2004 Sep; 110(13):1731-7. PubMed ID: 15381640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efficacy of disopyramide in the management of ventricular fibrillation storms in a patient with Brugada syndrome.
    Sumi S; Maruyama S; Shiga Y; Kodama S; Miyoshi K; Tojou H; Yamanouchi Y; Urata H
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):e53-6. PubMed ID: 20059716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome.
    Belhassen B; Viskin S; Fish R; Glick A; Setbon I; Eldar M
    J Cardiovasc Electrophysiol; 1999 Oct; 10(10):1301-12. PubMed ID: 10515552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry.
    Probst V; Veltmann C; Eckardt L; Meregalli PG; Gaita F; Tan HL; Babuty D; Sacher F; Giustetto C; Schulze-Bahr E; Borggrefe M; Haissaguerre M; Mabo P; Le Marec H; Wolpert C; Wilde AA
    Circulation; 2010 Feb; 121(5):635-43. PubMed ID: 20100972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU).
    Rosso R; Glick A; Glikson M; Wagshal A; Swissa M; Rosenhek S; Shetboun I; Khalamizer V; Fuchs T; Boulos M; Geist M; Strasberg B; Ilan M; Belhassen B;
    Isr Med Assoc J; 2008 Jun; 10(6):435-9. PubMed ID: 18669142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
    Conte G; Sieira J; Ciconte G; de Asmundis C; Chierchia GB; Baltogiannis G; Di Giovanni G; La Meir M; Wellens F; Czapla J; Wauters K; Levinstein M; Saitoh Y; Irfan G; Julià J; Pappaert G; Brugada P
    J Am Coll Cardiol; 2015 Mar; 65(9):879-88. PubMed ID: 25744005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification in patients with Brugada syndrome without previous cardiac arrest – prognostic value of combined risk factors.
    Okamura H; Kamakura T; Morita H; Tokioka K; Nakajima I; Wada M; Ishibashi K; Miyamoto K; Noda T; Aiba T; Nishii N; Nagase S; Shimizu W; Yasuda S; Ogawa H; Kamakura S; Ito H; Ohe T; Kusano KF
    Circ J; 2015; 79(2):310-7. PubMed ID: 25428522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment.
    Mizusawa Y; Sakurada H; Nishizaki M; Hiraoka M
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):359-64. PubMed ID: 16633076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into specific pro-arrhythmic triggers in Brugada and early repolarization syndromes: results of long-term follow-up.
    Talib AK; Sato N; Myojo T; Sugiyama E; Nakagawa N; Sakamoto N; Tanabe Y; Fujino T; Takeuchi T; Akasaka K; Matsuhashi H; Saijo Y; Kawamura Y; Doi A; Hasebe N
    Heart Vessels; 2016 Dec; 31(12):2035-2044. PubMed ID: 26968993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroquinidine therapy in Brugada syndrome.
    Hermida JS; Denjoy I; Clerc J; Extramiana F; Jarry G; Milliez P; Guicheney P; Di Fusco S; Rey JL; Cauchemez B; Leenhardt A
    J Am Coll Cardiol; 2004 May; 43(10):1853-60. PubMed ID: 15145111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.
    Priori SG; Gasparini M; Napolitano C; Della Bella P; Ottonelli AG; Sassone B; Giordano U; Pappone C; Mascioli G; Rossetti G; De Nardis R; Colombo M
    J Am Coll Cardiol; 2012 Jan; 59(1):37-45. PubMed ID: 22192666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk.
    Andorin A; Gourraud JB; Mansourati J; Fouchard S; le Marec H; Maury P; Mabo P; Hermida JS; Deharo JC; Delasalle B; Esnault S; Sadoul N; Davy JM; Leenhardt A; Klug D; Defaye P; Babuty D; Sacher F; Probst V
    Heart Rhythm; 2017 Aug; 14(8):1147-1154. PubMed ID: 28411139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of class-I antiarrhythmic drug test in the evaluation of patients with syncope: unmasking Brugada syndrome.
    Roos M; Sarkozy A; Brodbeck J; Henkens S; Chierchia GB; de Asmundis C; Capulzini L; Müller-Burri SA; Yakazi Y; Brugada P
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):290-5. PubMed ID: 21985403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents.
    Belhassen B; Shapira I; Shoshani D; Paredes A; Miller H; Laniado S
    Circulation; 1987 Apr; 75(4):809-16. PubMed ID: 3829343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phenotypic combination of idiopathic VF and Brugada syndrome.
    Martinek M; Purerfellner H
    Pacing Clin Electrophysiol; 2010 Sep; 33(9):e84-7. PubMed ID: 20230473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinidine-A legacy within the modern era of antiarrhythmic therapy.
    Vitali Serdoz L; Rittger H; Furlanello F; Bastian D
    Pharmacol Res; 2019 Jun; 144():257-263. PubMed ID: 31026503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope.
    Márquez MF; Rivera J; Hermosillo AG; Iturralde P; Colín L; Moragrega JL; Cárdenas M
    Pacing Clin Electrophysiol; 2005 Aug; 28(8):870-3. PubMed ID: 16105018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.